NYSE:ORCL

Oracle (ORCL)

127.94
-3.60 (2.74%)
as of Jul 14, 2026, 8:00:00 pm Market Open.
302 watching
0
Investor Insights
star iconJul 14, 2026, 12:00 am

This summary was created by AI, based on 45 opinions in the last 12 months.

Oracle Corporation is currently experiencing a challenging period, marked by a significant drop in stock performance and rising concerns over its high levels of debt. Recent reviews highlight the company's aggressive investments in AI and data centers, which could either lead to substantial long-term gains or exacerbate its financial struggles if not managed well. While some analysts express optimism about Oracle’s future profitability, particularly with potential earnings doubling by 2030, others caution that the high capital expenditure and debt load may hinder growth. Amidst this mixed sentiment, the company's upcoming earnings report is viewed with interest, as analysts seek clarity on its operational plans and financial health, given the uncertainty surrounding its cash flow and debt servicing capabilities.

consensus icon
Consensus
Mixed
valuation icon
Valuation
Overvalued
review icon
Similar
IBM
BUY

They just reported weaker sales and earnings numbers, but their cloud business--their data centre business is huge and rapidly growing.  Their backlog is nearly $100 billion. Gen AI is real. Rallied over 13% today.

BUY

It reports Tuesday. He added shares recently. It benefits from AI, cloud computing and data centres. All of them. Trades at a sedate 20x forward PE. Expects upgrades.

BUY ON WEAKNESS

It was down 5% yesterday after Salesforce's negative report. CRM's weak guidance won't impact Oracle's business. After Nvidia's infrastructure buildout, Oracle is next in line in this buildout, given their data centre buildout and the AI services they offer. Oracle will build these for Elon Musk's xAI among many other announcements. He added shares last week and today is a great time to step in.

Unspecified

Unsure on outlook of business. 

BUY

They had a good quarter and can go higher. He gave up too soon on this.

BUY ON WEAKNESS
ORCL vs. MSFT

Tough, because both are very fully priced. On any pullback of MSFT to around $410, you could pick it up.

ORCL is already through his price target. But he likes it so much, he's been selling calls against it. His 12-month price target was $126, and here it is almost $127. Running on all cylinders on both cloud and software.

If you own either, write calls. But if they roll over 5%, pick some up.

BUY

They screwed up their last two quarters, but delivered on their last, share up big because of AI. The CEO is good. He should have had more faith. Shares will likely keep rising and remain inexpensive.

HOLD

They had a bad quarter due to the impact of data centres they're building to fuel future growth. He wants an update about this and its effect on their margins. These centres are key to their long-term growth. A good hold now.

DON'T BUY

He took a loss on this after the company reported a bad quarter, even though ORCL insisted it was a good quarter. He has no time for such companies.

BUY

Reports Monday. A solid software company that trades at a reasonable PE and rarely misses earnings. But last time, they disappointed and shares plunged from $126 to $100. Some felt they overpaid for a second-tier electronic records company. Some feel they will leverage their huge data centre group into a gen-AI powerhouse. Wall Street has fallen back in love with AI, which has helped stocks recover.

PARTIAL SELL

His 12-month price target is $132. Last report beat on top and bottom, but conservative guidance. Behemoth. Lots of AI partnerships. Cross-selling. Trim in mid-$120s. Re-enter at $110 and $105. Probably won't go below $100.

(Analysts’ price target is $126.00)
RISKY

The CEO says that its data centre cloud AI business is on fire, which he believes. Also, this trades at only 19x PE and shares are well off its highs.

TOP PICK

He targets $126, a decent runway. They have 3 business units: cloud/licensing (are #4 in cloud), legacy hardware, and services (they've added more products). Earlier this month, introduced a gen-AI product that's interesting. Can buy now and more at $97 then $91.

(Analysts’ price target is $127.43)
BUY

Good valuation to buy and hold now.

PAST TOP PICK
(A Top Pick Oct 13/22, Up 76%)

Still runway, 12-month price target of $126. Lots of collaborations. Coming out with AI capabilities. September reporting beat on top and bottom. Any disappointment on earnings is because newly acquired Cerner was not yet brought in. Tremendous buy here.

Showing 76 to 90 of 377 entries